Abstract
Introduction:
Pharmaceutical companies are on the hunt for new product and technology
opportunities to augment their product development pipelines. Pharmaceutical
giants and big biotech alike are exploring new avenues of cooperation to gain
early access to innovation as they move toward external R&D models and
establish corporate venturing infrastructures. Competition is fi erce. Right
now, innovation is the currency of the industry; it greases the wheels of
dealmaking, and its value is measured in the 4,030 products that were licensed
between 2005 and 2007 and the 15 drug licensing trends that this dealmaking is
spawning.
Get the Answers You Need to Shape Your Strategy:
- The near-term outlook for the pharmaceutical industry is not encouraging.
What is pharma' s new externalized R&D business model, and why is it
important?
- Patent expiries and disruption from biogenerics are two of the biggest
concerns looming in the industry right now. What are companies doing to
improve the outlook for their productivity and performance? What are the most
effi cient strategies for building value now? How do these strategies make
drug development more successful?
- Pharma is currently in an innovation defi cit. What vehicles are in
play for accessing innovation, and what trends are developing?
- Strategic opportunities such as licensing and partner deals among big
pharma, biotech, and specialty pharmaceutical companies are driving pipeline
development. What are the latest dealmaking strategies? What are some of
the big alliance deals already in motion?
Scope:
- Expert commentaries: analysis of corporate venturing and
value-added drug development by two industry experts.
- Mounting industry pressures: increasing regulatory oversight;
rising development costs and productivity problems; looming patent expiries;
generics competition; and disruption from biogenerics.
- Externalization trends in business practices: a new R&D model;
corporate venturing and innovation incubators to gain access to early-stage
innovation.
- Value-building opportunities: harnessing external innovation to
improve a product' s characteristics; chemical modifi cation as a
value-building opportunity.
- Acquiring innovation: a look at 4,030 products involved in product
deals from 2000-2007; fortifying pipelines via deal structures for product
acquisition, inlicensing, outlicensing, and joint ventures; late-stage product
inlicensing trends, 2005-2007.
- Big pharma' s inlicensed product deals: pharmaceutical companies tap
new resources by inlicensing late-stage products; inlicensed product
portfolios of nine major pharmaceutical companies; strategies used by
different companies.
- Recent dealmaking activities: an analysis of 15 trends infl uencing
the drug licensing landscape.
View Cart
